EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)

Rajiv Agarwal iD, Jennifer B Green iD, Hiddo J L Heerspink iD, Johannes F E Mann, Janet B McGill, Amy K Mottl iD, Masaomi Nangaku, Julio Rosenstock iD, Muthiah Vaduganathan iD, Meike Brinker, Charlie Scott, Li Li und 3 weitere

Diabetes Care · 2025

DOI: 10.2337/dc25-1673 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2025. Verfasst von Rajiv Agarwal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, IN. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Diabetes Mellitus, Type 2, Albuminuria. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Pharmaceuticals Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE The CONFIDENCE trial demonstrated additive benefits of simultaneous initiation of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, and a sodium–glucose cotransporter 2 (SGLT2) inhibitor compared with monotherapy in reducing the urinary albumin-to-creatinine ratio (UACR). This prespecified analysis evaluated whether safety and efficacy of combination therapy varies by baseline glucagon-like peptide 1 receptor agonist (GLP-1 RA) use. RESEARCH DESIGN AND METHODS Adults with chronic kidney disease (UACR ≥100 to <5,000 mg/g; estimated glomerular filtration rate [eGFR] 30–90 mL/min/1.73 m2) and type 2 diabetes (glycated hemoglobin <11% [97 mmol/mol]) were randomized (1:1:1) to once-daily finerenone, empagliflozin, or finerenone plus empagliflozin. RESULTS Among 800 participants, 182 (23%) used a GLP-1 RA at baseline. At day 180, UACR change from baseline in participants using a GLP-1 RA was −51% (95% CI −59 to −40%) with combination therapy, −34% (−48 to −18%) with finerenone, and −36% (−48 to −21%) with empagliflozin. Corresponding results in those not using a GLP-1 RA at baseline were −56% (−62 to −50%), −37% (−45 to −28%), and −33% (−41 to −23%), respectively. Hyperkalemia incidence rates with combination therapy were 9.0% and 9.5% among individuals with and without baseline GLP-1 RA use. eGFR changes were consistent among individuals with and without baseline GLP-1 RA use. Acute kidney injury was uncommon. Decreases in systolic blood pressure were observed and were more pronounced with combination therapy. CONCLUSIONS In CONFIDENCE, simultaneous initiation with finerenone and an SGLT2 inhibitor was effective and well tolerated compared with monotherapy, irrespective of background use of a GLP-1 RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesDiabetes Mellitus, Type 2AlbuminuriaRenal Insufficiency, ChronicGlucagon-Like Peptide-1 Receptor AgonistsNaphthyridinesHumansFemaleMaleMiddle AgedAgedDrug Therapy, CombinationSodium-Glucose Transporter 2 InhibitorsGlomerular Filtration RateHypoglycemic Agents

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesfinerenoneGlucagon-Like Peptide-1 Receptor AgonistsNaphthyridinesSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, IN.
  • Indiana University School of Medicine, Indianapolis, IN.
  • Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • KfH Kidney Centre, Munich, Germany.
  • Department of Nephrology and Hypertension, Friedrich Alexander University, Erlangen, Germany.

ORCID-Profile: Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, Amy K Mottl, Julio Rosenstock, Muthiah Vaduganathan, Peter Rossing

Förderung

  • Pharmaceuticals Bayer

Zitieren

APA

Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., Vaduganathan, M., Brinker, M., Scott, C., Li, L., Li, N., Rohwedder, K., & Rossing, P. (2025). Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial). Diabetes Care. https://doi.org/10.2337/dc25-1673

Vancouver

Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial). Diabetes Care. 2025. doi:10.2337/dc25-1673

BibTeX
@article{Agarwal2025,
  author = {Agarwal, Rajiv and Green, Jennifer B and Heerspink, Hiddo J L and Mann, Johannes F E and McGill, Janet B and Mottl, Amy K and Nangaku, Masaomi and Rosenstock, Julio and Vaduganathan, Muthiah and Brinker, Meike and Scott, Charlie and Li, Li and Li, Na and Rohwedder, Katja and Rossing, Peter},
  title = {Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)},
  journal = {Diabetes Care},
  year = {2025},
  doi = {10.2337/dc25-1673}
}
Kostenlos starten →